Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company founded in 2013 with a mission to revolutionize the field of synthetic biology through scalable, precise, and cost-effective DNA synthesis. Headquartered in South San Francisco, the company was co-founded by Dr. Emily Leproust, who has become a recognized leader in genomics and synthetic DNA. From its earliest days, Twist set out to transform how DNA is manufactured by moving away from traditional methods and instead using a proprietary silicon-based platform to miniaturize the chemistry required for gene synthesis. This breakthrough approach allowed Twist to create DNA at an unprecedented scale, speed, and accuracy, giving it a unique position in the market.
The company’s platform has since become a cornerstone technology that powers discovery and innovation across multiple industries. Twist provides synthetic DNA tools and services that enable advancements in medicine, agriculture, industrial chemicals, and even data storage. Its silicon-based platform overcomes inefficiencies in traditional DNA synthesis by offering high-throughput, rapid, and precise solutions, allowing researchers and commercial partners to design and test applications that were previously too costly or time-consuming. As a result, Twist has attracted a diverse customer base ranging from top pharmaceutical companies and academic institutions to startups working on next-generation solutions in biotechnology and sustainability.
Twist’s expertise extends beyond DNA synthesis into specialized solutions through Twist Biopharma Solutions, its biologics discovery and optimization arm. This division integrates the company’s DNA synthesis capabilities with antibody engineering, bioinformatics, and in vivo and in vitro discovery methods to create comprehensive antibody libraries. These resources serve as powerful tools for partners working in drug discovery, particularly in the fast-growing field of antibody therapeutics. By leveraging automation, data-driven design, and scalable production, Twist has positioned itself as a partner of choice for biopharma companies developing cutting-edge therapies, including antibody-drug conjugates and other precision medicines.
Over the years, Twist Bioscience has also shown consistent revenue growth as demand for synthetic DNA continues to rise. The company has become known not only for its scientific innovation but also for its ability to execute on a commercial scale, with revenues climbing year over year and guidance reaffirming continued double-digit growth into the future. Partnerships with leading research and therapeutics companies underscore its credibility, while investments from major institutional investors reflect growing confidence in Twist’s long-term vision.
What makes Twist especially compelling is its role as an enabler of innovation across industries. In medicine, its tools are helping to accelerate drug discovery and personalized therapies. In agriculture, its products are supporting the development of more sustainable crops. In industrial applications, Twist’s DNA synthesis enables the design of organisms that can produce renewable materials or chemicals more efficiently. The company is even exploring DNA-based data storage as a futuristic solution for the exponential growth of digital information. This breadth of application underscores the scalability and versatility of its platform, making Twist not just a biotech company but a foundational player in the emerging bioeconomy.
By consistently advancing its technology, expanding its partnerships, and addressing some of the most pressing challenges across healthcare, agriculture, and sustainability, Twist Bioscience has firmly established itself as a leader in synthetic biology. With its silicon-based DNA synthesis platform, world-class expertise, and vision to accelerate global innovation, the company continues to set the pace for what is possible in biotechnology, offering both near-term growth potential and long-term transformative impact.
Strategic Collaboration with Synthetic Design Lab Signals Growth
One of the most recent and powerful catalysts for Twist Bioscience is its collaboration with Synthetic Design Lab (SDL), a next-generation therapeutics company. The partnership underscores Twist’s expanding influence in the discovery and development of antibody-drug conjugates (ADCs), which are among the fastest-growing modalities in oncology. Twist’s high-throughput DNA synthesis expertise and its ability to build unbiased, diverse antibody libraries provide SDL with the necessary tools to advance its proprietary SYNTHBODY platform. Together, the two companies are aiming to design antibody therapeutics that are more advanced, more precise, and more effective than those currently available in cancer treatment.
This collaboration validates Twist’s platform technology and highlights its ability to act as a force multiplier for biotech partners, reinforcing its reputation as an essential engine powering therapeutic innovation. As ADCs continue to attract billions in investment and dominate oncology pipelines, Twist stands to capture significant upside by being at the forefront of the discovery process.
CHECK THIS OUT: Saudi Arabia Wants CEL-SCI (CVM)’s Multikine Now! and Aligos Therapeutics (ALGS) Doubles Cash to $122.9M.
Twist Biopharma Solutions: The Discovery Engine for the Future
Twist’s Biopharma Solutions division plays a critical role in its long-term growth strategy. By combining DNA synthesis with in vivo, in vitro, and in silico discovery methods, Twist offers end-to-end antibody discovery services tailored to partner needs. Its proprietary antibody libraries serve as a vast and unbiased resource, expediting therapeutic discovery and lowering the risk of clinical failure. Automated screening and panning technologies enable the rapid identification of high-affinity antibody leads that can quickly progress into clinical pipelines.
This capability has made Twist an indispensable partner for companies looking to accelerate their preclinical programs. From IgG conversion and purification to biophysical and functional characterization, Twist provides a complete infrastructure that reduces development timelines. The SDL collaboration is one high-profile example of how Twist’s platform creates value across the therapeutic continuum, but dozens of similar partnerships globally reinforce its ability to scale revenues as demand for synthetic biology intensifies.
Strong Financial Performance and Expanding Market Reach
Twist has demonstrated consistent revenue growth, fueled by the expansion of synthetic DNA demand. In fiscal 2025, Twist reported quarterly revenue of approximately $798.6 million across its divisions, including robust contributions from its Biopharma Solutions unit. Revenue growth has averaged over 20% year-over-year, and management reaffirmed guidance for fiscal 2025 with projections for continued double-digit expansion into 2026. Analysts forecast Twist’s revenue to reach $437.9 million in FY2026, reflecting sustained demand for its DNA tools and partnerships with leading biopharma players.
Financial discipline has been equally important. By focusing on scaling manufacturing efficiency and investing in automation, Twist has improved gross margins while managing costs, paving a path toward profitability in the coming years. Its ability to fund operations and expand capacity without compromising innovation provides investors with confidence that growth will remain consistent over the long term.
Analyst Confidence and Institutional Backing
Wall Street sentiment remains overwhelmingly positive toward Twist Bioscience. Thirteen analysts currently rate the stock a Buy, with target prices averaging $40 per share, implying nearly 46% upside potential from current trading levels. High-profile institutions including Vanguard, ARK Investment Management, and Russell Investments have built significant positions in TWST, highlighting strong institutional conviction in its future.
This confidence reflects Twist’s unique positioning in synthetic biology as a market leader. Unlike many small-cap biotech companies that are still pre-commercial, Twist has established recurring revenue streams, an expanding customer base, and a track record of execution that de-risks the investment case.
Market Leadership in Synthetic Biology and Beyond
Synthetic biology is projected to become a $56 billion global market by 2028, and Twist is positioned as one of its primary beneficiaries. The company’s DNA synthesis platform underpins advancements not just in biopharma but also in agriculture, sustainable materials, and even data storage, where DNA is being explored as a long-term archival medium. By leveraging its platform across multiple industries, Twist diversifies its revenue sources and mitigates risks associated with reliance on any single therapeutic area.
The recent collaboration with Synthetic Design Lab highlights Twist’s leadership in biopharma, but its platform is equally capable of supporting innovations in food production, renewable energy, and bio-defense. This breadth of application reinforces Twist’s long-term growth potential and strategic importance.
Conclusion: A Bullish Case for Twist Bioscience
Twist Bioscience embodies the qualities investors seek in a growth biotech: a disruptive technology platform, strong financial performance, strategic collaborations, and vast market opportunity. The company’s partnership with Synthetic Design Lab shines a spotlight on its ability to drive innovation in antibody-drug conjugates, one of the most exciting areas of cancer research today. Its Biopharma Solutions unit has become a discovery engine for therapeutic pipelines worldwide, while its DNA synthesis technology continues to transform industries well beyond healthcare.
With expanding revenues, improving margins, bullish analyst sentiment, and institutional backing, Twist Bioscience is well positioned to deliver substantial shareholder value. As synthetic biology grows into a global multi-billion-dollar industry, Twist’s role as a leading DNA manufacturer makes it a company with extraordinary upside potential. For long-term investors, Twist Bioscience (NASDAQ: TWST) stands out as a high-conviction bullish opportunity in the biotechnology sector.
READ ALSO: Exact Sciences (EXAS) Just Made Cancer Detection 100x Easier! and Soleno Therapeutics (SLNO): The Biotech Company That Could Make You Rich.
